EFFICACY AND SAFETY OF ANTI-TNFα HUMAN MONOCLONAL ANTIBODIES IN CHILDREN WITH JUVENILE IDIOPATHIC ARTHRITIS AND SECONDARY RESISTANCE TO OTHER GENETICALLY ENGINEERED BIOLOGICAL AGENTS

Treatment of juvenile idiopathic arthritis (JIA) is one of the most important challenges in paediatric rheumatology. The results of the retrospective observational study of adalimumab (anti TNF human monoclonal antibodies) efficacy and safety in real clinical practice in treatment of 56 patients wit...

ver descrição completa

Detalhes bibliográficos

Principais autores:	E. I. Alexeeva, T. M. Bzarova, S. I. Valieva, R. V. Denisova, K. B. Isaeva, A. M. Chomakhidze, E. G. Chistyakova, T. V. Sleptsova, E. V. Mitenko, N. I. Taibulatov
Formato:	Artigo
Idioma:	Inglês
Publicado em:	"Paediatrician" Publishers LLC 2012-07-01
coleção:	Вопросы современной педиатрии
Assuntos:	children juvenile idiopathic arthritis adalimumab treatrment tnfα-blockers resistance genetically engineered agents
Acesso em linha:	https://vsp.spr-journal.ru/jour/article/view/458
Tags:	Adicionar Tag Sem tags, seja o primeiro a adicionar uma tag!